



Ref: SEC/SE/2023-24  
Date: October 18, 2023

To,  
Corporate Relations Department  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block Bandra Kurla Complex  
Bandra (E), Mumbai – 400051

BSE Scrip Code: 500096

NSE Scrip Symbol: DABUR

**Sub: Submission of Information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to provisions of Regulation 30 read with sub-para 8 of Para B of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as amended, we hereby submit the disclosure regarding litigation(s) pending in the United States of America, against Namaste Laboratories LLC ("Namaste"), Dermoviva Skin Essentials Inc. ("Dermoviva") and Dabur International Ltd. ("DINTL"), all of which are subsidiaries of Dabur India Limited.

Currently, the cases are in the pleadings and early discovery phases of litigation. There are various motions pending as well. Since we are in the initial stage of litigation, any final quantum of claim amount is neither probable nor estimable. However, the Company is disclosing the details of aforesaid pending litigations, since the cumulative value of impact on account of legal defence cost is expected to breach the materiality threshold under the Listing Regulations.

Details of the above Litigation(s) as required under Regulation 30 of Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are given below:

Name of the opposing party	Plaintiffs- Mass-tort litigation in the United States consisting of multiple parties.  Defendants- Namaste Laboratories LLC ("Namaste"), Dermoviva Skin Essentials Inc. ("Dermoviva") and Dabur International Ltd. ("DINTL") - all of which are subsidiaries of Dabur India Limited, among others, have been named as defendants.
Court/ Tribunal/ agency where litigation is filed	Cases have been filed in both federal and state courts in the United States and in Canada. The federal cases were consolidated as a Multi-District Litigation, also referred to as MDL, before the United States District Court for the Northern District of Illinois.



<p>Brief details of dispute/litigation</p>	<p>Certain consumers in the hair relaxer product industry have alleged that some industry players / defendants sold and/or manufactured hair relaxer products that contain certain chemicals and that the use of these hair relaxer product has caused ovarian cancer, uterine cancer and other health issues in the users.</p> <p>Currently there are approximately 5400 cases in the MDL which name Namaste, Dermoviva and DINTL as defendants along with certain other industry players.</p> <p>Namaste, Dermoviva and DINTL deny liability and have retained counsel to defend them in these lawsuits as these allegations are based on unsubstantiated and incomplete study.</p> <p>Currently, the cases are in the pleadings and early discovery phases of litigation, which means the parties are challenging the adequacy of the plaintiffs' complaints and, in some cases, exchanging requests for information and documents. There are various motions pending as well.</p>
<p>Expected financial implications, if any, due to compensation, penalty etc.;</p>	<p>At this stage of the litigation, any financial implication due to settlement or verdict outcome cannot be determined. However, the defense costs for the litigation is expected to breach the materiality threshold, in the near future.</p>
<p>Quantum of claims, if any;</p>	<p>At this stage of the litigation, settlement or verdict outcome cannot be determined. Since we are in the initial stage of litigation, any final claim settlement amount is neither probable nor estimable.</p>

This is for your information and records.

Thanking You,

Yours faithfully,  
For **Dabur India Limited**

**(A K Jain)**  
**EVP (Finance) and Company Secretary**